Wall Street analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to post earnings per share (EPS) of ($0.11) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.06). Collegium Pharmaceutical reported earnings of ($0.45) per share in the same quarter last year, which would indicate a positive year over year growth rate of 75.6%. The business is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.
On average, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.49). For the next financial year, analysts forecast that the business will post earnings of $0.60 per share, with EPS estimates ranging from $0.00 to $1.20. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.02. The firm had revenue of $73.10 million for the quarter, compared to the consensus estimate of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The company’s revenue was up 1930.6% compared to the same quarter last year.
Several analysts have weighed in on COLL shares. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Cantor Fitzgerald cut their target price on Collegium Pharmaceutical from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, August 9th. Janney Montgomery Scott set a $27.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Monday, August 6th. Piper Jaffray Companies set a $34.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, July 11th. Finally, BidaskClub downgraded Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $31.71.
Institutional investors and hedge funds have recently bought and sold shares of the company. Atria Investments LLC bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth $201,000. Cubist Systematic Strategies LLC bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth $213,000. EagleClaw Capital Managment LLC bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $220,000. Stifel Financial Corp bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $224,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $260,000. 93.57% of the stock is currently owned by institutional investors.
Shares of Collegium Pharmaceutical stock opened at $14.74 on Friday. The company has a debt-to-equity ratio of 3.94, a quick ratio of 0.78 and a current ratio of 0.82. The firm has a market cap of $492.35 million, a price-to-earnings ratio of -5.97 and a beta of 0.39. Collegium Pharmaceutical has a 1-year low of $9.01 and a 1-year high of $29.90.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Featured Article: Exchange-Traded Funds (ETFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.